OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
0.7501
-0.1221 (-14.00%)
Nov 12, 2026, 4:00 PM EST - Market closed
OS Therapies Employees
As of December 31, 2025, OS Therapies had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees did not change compared to the previous year. That makes OS Therapies the 41,880th largest employer in the world and 6,491st in the United States.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$7,873,916
Market Cap
34.66M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - | 4 | 1 |
| Dec 31, 2024 | 5 | 1 | 25.00% | 4 | 1 |
| Mar 31, 2024 | 4 | 0 | - | 3 | 1 |
| Sep 30, 2023 | 4 | 0 | - | 3 | 1 |
| Mar 31, 2023 | 4 | - | - | 3 | 1 |
| Dec 31, 2022 | 4 | - | - | 3 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Caribou Biosciences | 97 |
| Alps Group | 93 |
| IRulya Therapeutics | 38 |
| ImageneBio | 18 |
| Instil Bio | 17 |
| Serina Therapeutics | 16 |
| Apollomics | 14 |
| Hyperion DeFi | 9 |
OSTX News
- 2 days ago - OS Therapies Initiates U.K. MHRA Conditional Marketing Authorisation Application for Herlystic (OST-HER2) in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma - Newsfile Corp
- 7 days ago - OS Therapies price target lowered to $6 from $7 at Roth Capital - TheFly
- 7 days ago - OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial - Newsfile Corp
- 24 days ago - OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million - Newsfile Corp
- 5 weeks ago - Rubenstein Public Relations Named Agency of Record for OS Therapies - GlobeNewsWire
- 5 weeks ago - OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma - Newsfile Corp
- 5 weeks ago - OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial - Newsfile Corp
- 6 weeks ago - OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer - Newsfile Corp